ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Takeda inks two development pacts

by Rick Mullin
July 11, 2016 | APPEARED IN VOLUME 94, ISSUE 28

Takeda Pharmaceuticals will work with Belgium’s TiGenix to develop the latter’s stem cell therapy for Crohn’s disease outside the U.S. TiGenix will receive an up-front payment of $28 million, as well as potential milestone and royalty payments. Takeda also will invest $11 million in the Belgian firm. Separately, Takeda is forming a partnership with Altos Therapeutics to develop Altos’s ATC-1906, an oral dopamine D2/D3 receptor antagonist, for the treatment of gastroparesis. The agreement gives Takeda an exclusive option to acquire Altos through Phase I development of the drug.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment